CN112535729A - Composition with effect of preventing and treating complications of dialysis patients and preparation method and application thereof - Google Patents
Composition with effect of preventing and treating complications of dialysis patients and preparation method and application thereof Download PDFInfo
- Publication number
- CN112535729A CN112535729A CN202010902260.3A CN202010902260A CN112535729A CN 112535729 A CN112535729 A CN 112535729A CN 202010902260 A CN202010902260 A CN 202010902260A CN 112535729 A CN112535729 A CN 112535729A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- dialysis
- patients
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 135
- 238000000502 dialysis Methods 0.000 title claims abstract description 111
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 230000000694 effects Effects 0.000 title abstract description 18
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 53
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000011574 phosphorus Substances 0.000 claims abstract description 41
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 41
- 235000018102 proteins Nutrition 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000011591 potassium Substances 0.000 claims abstract description 39
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 39
- 239000005018 casein Substances 0.000 claims abstract description 34
- 235000021240 caseins Nutrition 0.000 claims abstract description 34
- 239000006188 syrup Substances 0.000 claims abstract description 34
- 235000020357 syrup Nutrition 0.000 claims abstract description 34
- 240000008042 Zea mays Species 0.000 claims abstract description 31
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 31
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 31
- 235000005822 corn Nutrition 0.000 claims abstract description 31
- 235000019198 oils Nutrition 0.000 claims abstract description 31
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 30
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 30
- 235000020238 sunflower seed Nutrition 0.000 claims abstract description 30
- 235000021119 whey protein Nutrition 0.000 claims abstract description 30
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 29
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 29
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 29
- 208000002682 Hyperkalemia Diseases 0.000 claims abstract description 15
- 201000005991 hyperphosphatemia Diseases 0.000 claims abstract description 13
- 108010076119 Caseins Proteins 0.000 claims description 49
- 102000011632 Caseins Human genes 0.000 claims description 49
- 229960003975 potassium Drugs 0.000 claims description 34
- 108010033929 calcium caseinate Proteins 0.000 claims description 16
- 229940080237 sodium caseinate Drugs 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 15
- 239000011734 sodium Substances 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- 208000007502 anemia Diseases 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 239000011573 trace mineral Substances 0.000 claims description 10
- 235000013619 trace mineral Nutrition 0.000 claims description 10
- 238000001631 haemodialysis Methods 0.000 claims description 9
- 230000000322 hemodialysis Effects 0.000 claims description 9
- 208000020832 chronic kidney disease Diseases 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 208000001953 Hypotension Diseases 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 229940071162 caseinate Drugs 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 230000036543 hypotension Effects 0.000 claims description 5
- 206010038464 renal hypertension Diseases 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 208000029422 Hypernatremia Diseases 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 229930003756 Vitamin B7 Natural products 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 229930003448 Vitamin K Natural products 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000011912 vitamin B7 Nutrition 0.000 claims description 3
- 239000011735 vitamin B7 Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 235000019168 vitamin K Nutrition 0.000 claims description 3
- 239000011712 vitamin K Substances 0.000 claims description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 229940046010 vitamin k Drugs 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 230000004872 arterial blood pressure Effects 0.000 claims description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 1
- 229930003451 Vitamin B1 Natural products 0.000 claims 1
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- 229930003471 Vitamin B2 Natural products 0.000 claims 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 229960003495 thiamine Drugs 0.000 claims 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 1
- 235000010374 vitamin B1 Nutrition 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 235000019164 vitamin B2 Nutrition 0.000 claims 1
- 235000019158 vitamin B6 Nutrition 0.000 claims 1
- 229940011671 vitamin b6 Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 40
- 239000008280 blood Substances 0.000 abstract description 40
- 208000002720 Malnutrition Diseases 0.000 abstract description 18
- 235000000824 malnutrition Nutrition 0.000 abstract description 15
- 230000001071 malnutrition Effects 0.000 abstract description 15
- 208000015380 nutritional deficiency disease Diseases 0.000 abstract description 15
- 239000007788 liquid Substances 0.000 abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 14
- 206010020772 Hypertension Diseases 0.000 abstract description 9
- 230000006378 damage Effects 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 230000003204 osmotic effect Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 26
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 20
- 235000016709 nutrition Nutrition 0.000 description 17
- 239000000843 powder Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 11
- 229910052742 iron Inorganic materials 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 11
- 230000035764 nutrition Effects 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 229940032147 starch Drugs 0.000 description 11
- 239000008107 starch Substances 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 239000003173 antianemic agent Substances 0.000 description 8
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 206010067484 Adverse reaction Diseases 0.000 description 7
- 230000006838 adverse reaction Effects 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000013589 supplement Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920000881 Modified starch Polymers 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 208000017169 kidney disease Diseases 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 241001070941 Castanea Species 0.000 description 5
- 235000014036 Castanea Nutrition 0.000 description 5
- 230000006793 arrhythmia Effects 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 235000013599 spices Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000007211 cardiovascular event Effects 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000019426 modified starch Nutrition 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 108010071690 Prealbumin Proteins 0.000 description 3
- 102000007584 Prealbumin Human genes 0.000 description 3
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 235000021537 Beetroot Nutrition 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010070476 Haemodialysis complication Diseases 0.000 description 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 208000005475 Vascular calcification Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 229960004998 acesulfame potassium Drugs 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
- 239000001639 calcium acetate Substances 0.000 description 2
- 235000011092 calcium acetate Nutrition 0.000 description 2
- 229960005147 calcium acetate Drugs 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229930003836 cresol Natural products 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 102000044890 human EPO Human genes 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960001518 levocarnitine Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229940001607 sodium bisulfite Drugs 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229940001482 sodium sulfite Drugs 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- -1 sorbitan fatty acid Chemical class 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 208000004884 Balkan Nephropathy Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000004672 Cardiovascular Infections Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 229910017569 La2(CO3)3 Inorganic materials 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- KHNXRSIBRKBJDI-UHFFFAOYSA-N Sevelamer hydrochloride Chemical compound Cl.NCC=C.ClCC1CO1 KHNXRSIBRKBJDI-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 108010067454 caseinomacropeptide Proteins 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 229940032296 ferric chloride Drugs 0.000 description 1
- 239000011706 ferric diphosphate Substances 0.000 description 1
- 235000007144 ferric diphosphate Nutrition 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- 229960005191 ferric oxide Drugs 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 229940036404 ferric pyrophosphate Drugs 0.000 description 1
- 229940032950 ferric sulfate Drugs 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229910000399 iron(III) phosphate Inorganic materials 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 description 1
- 229960001633 lanthanum carbonate Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000008979 phosphorus utilization Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 1
- 229960003693 sevelamer Drugs 0.000 description 1
- 229960003027 sevelamer hydrochloride Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- GYHCTFXIZSNGJT-UHFFFAOYSA-N tolvaptan Chemical compound CC1=CC=CC=C1C(=O)NC(C=C1C)=CC=C1C(=O)N1C2=CC=C(Cl)C=C2C(O)CCC1 GYHCTFXIZSNGJT-UHFFFAOYSA-N 0.000 description 1
- 229960001256 tolvaptan Drugs 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a composition with the effect of preventing and treating complications of dialysis patients, a preparation method and application thereof, wherein the composition comprises 5-33 parts of whey protein, 1-20 parts of casein or casein salt, 1-50 parts of maltodextrin, 1-10 parts of corn syrup and 5-75 parts of sunflower seed oil, the blood potassium level can be controlled to be lower than 5.0mmol/L, the blood phosphorus level can be controlled to be lower than 1.78mmol/L, the complications of protein malnutrition, hyperphosphatemia, hyperkalemia, hypertension and the like of dialysis patients are comprehensively improved, the dialysis interval time of the dialysis patients is prolonged, and the harm of dialysis to bodies is reduced. In addition, each unit dose is prepared by 60mL of water, so that the liquid intake burden is reduced, the osmotic pressure of the human body is equivalent, the gastrointestinal tract tolerance is better, and the patient compliance is higher.
Description
The application is a divisional application of Chinese patent application with application date of 2019, 9 and 20, application number of 201910890455.8 and invention name of 'a composition with effect of preventing and treating complications of dialysis patients, a preparation method and application thereof'.
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to a composition with an effect of preventing and treating complications of dialysis patients, and a preparation method and application thereof.
Background
Dialysis therapy by hemodialysis and/or peritoneal dialysis, the components (e.g., solutes or water, etc.) in the body fluid of a dialysis patient are removed from the body through a semipermeable membrane. Hemodialysis utilizes the principle of a semipermeable membrane to discharge various harmful metabolites and excessive electrolytes in vivo out of the body through diffusion, purify blood of a patient, correct water electrolytes, correct acid-base balance and the like. Peritoneal dialysis utilizes the peritoneum as a semi-permeable membrane, and utilizes the action of gravity to fill prepared dialysate into the peritoneal cavity of a patient through a catheter, and then removes in vivo metabolites and toxic substances, corrects water and electrolyte balance disorder of the patient and the like by continuously replacing the peritoneal dialysate.
The long-term dialysis causes protein and energy imbalance, hyperphosphatemia, hyperkalemia, renal hypertension, hypotension after dialysis, anemia and other complications of patients caused by malnutrition, reduces the quality of life of dialysis patients, increases the hospitalization rate of patients, shortens the life of patients, even increases the death risk of patients and the like.
1. Protein energy malnutrition. Dialysis patients are generally in a state of malnutrition including protein energy malnutrition, and an absolute or relative insufficient intake of nutrients such as protein calories, which leads to a decrease in protein stores in the body or a decrease in body fat. Most dialysis patients have reduced appetite, and hunger sensation is an adaptive reaction of their bodies, and malnutrition can be corrected by supplementing nutrients. Due to the action of various factors such as chronic renal failure toxin, gastrointestinal dysfunction, inflammation, etc., muscle protein is consumed in the body of a dialysis patient, and adipose tissue is preserved and accumulated to cause a consumption state. Studies have shown that 90% of dialysis patients suffer from protein energy malnutrition, wherein peritoneal dialysis patients lose 10.5g of protein per day and hemodialysis patients lose 10g to 12g of amino acids and peptides per day. Loss of protein nutrition and insufficient energy cause various serious complications including cardiovascular diseases, infection and the like, so that the quality of life of dialysis patients is reduced, the life cycle is shortened, and even the death risk is increased. The protein intake of dialysis population is recommended to be 1.2-1.3g/kg/d and the energy intake is recommended to be 30-35kcal/kg/d in the American nutrient guideline for dialysis patients and the Chinese consensus on protein nutrition treatment for chronic kidney diseases.
2. Hyperphosphatemia. The protein and phosphorus in natural foods are tightly bound. Hyperphosphatemia is inevitably induced by a high protein diet of dialysis patients. The Chinese medical society of Kidney science, division "Chronic Kidney disease mineral and bone abnormality diagnosis and treatment guide" suggests that the maximum benefit is gained by maintaining the blood phosphorus level of dialysis patients at 1.13-1.78 mmol/L. The incidence of hyperphosphatemia of dialysis patients in various countries around the world is high, and about 34.2 percent of patients have more than 1.78mmol/L of blood phosphorus. The average value of the blood phosphorus of dialysis patients in China is even as high as 2.01 mmol/L. Hyperphosphatemia causes mineral and bone metabolic disorders, secondary hyperparathyroidism and vascular calcification of patients, and increases the cardiovascular and cerebrovascular events and death risks of patients. High serum phosphorus levels cause binding of phosphorus to calcium in the blood, leading to ectopic calcification and the initiation of arteriosclerosis. Currently, phosphorus binders (such as sevelamer hydrochloride and precipitated calcium carbonate) are mostly used to reduce serum phosphorus levels, but phosphorus is not fully utilized in the state of myolysis and hypoplasia, and the reduction of serum phosphorus levels is only considered as symptomatic therapy, and it is desired to improve the blood phosphorus utilization rate by controlling the serum phosphorus levels of patients within a suitable range.
3. Hyperkalemia. Hyperkalemia (the concentration of potassium ions in the blood of a patient is higher than 5.0mmol/L) is one of the common electrolyte disorder complications of dialysis patients, and the food and/or drug influence of the patients is usually related to acidosis, digestive tract bleeding, uncontrolled diabetes, iatrogenic factors and the like of the patients. The hyperkalemia causes symptoms of a cardiovascular system and a neuromuscular system of a dialysis patient in clinic, so that the patient has symptoms of arrhythmia, numbness of limbs, muscle ache, asphyxia and the like, and the patient has abdominal pain and metabolic acidosis, thereby seriously affecting the life quality of the patient, shortening the life cycle of the patient and even increasing the death risk.
4. Renal hypertension and post-dialysis hypotension. 80% -90% of dialysis patients develop hypertension, and the patients are ideally dialyzed thoroughly for dry weight control, and when combined with Angiotensin Converting Enzyme Inhibitors (ACEI) or angiotensin II receptor blockers, calcium antagonists and beta blockers, only about 30% of patients have effective blood pressure control, and about 50% of dialysis patients still develop hypertension. Some patients have a difficult-to-correct hypotensive state during dialysis, and most of the above-mentioned adverse symptoms occur in dialysis patients for elderly patients or dialysis patients for diabetic renal failure.
5. Anemia is caused. The main cause of anemia in dialysis patients is the disorder of the hematopoietic hormone Erythropoietin (EPO) production of the patients. The clinical practice usually adopts supplementation of erythropoiesis stimulating factors (ESAs) and iron agents to correct renal anemia in patients. However, exogenous supplementation of ESAs preparations and iron agents has inevitable side effects or adverse reactions, and dialysis patients with malnutrition often show low response ESAs, so that the ESAs preparations need to be administered in large doses, and the side effects or adverse reactions caused thereby are more remarkable.
Currently, there are a number of challenges in improving complications in dialysis patients.
First, the complications of dialysis patients are influenced by multiple factors that are causal and vicious cycles to each other. Nutritional supplementation and dialysis are the primary means of maintaining a patient's energy protein metabolic balance and homeostasis. The nutrition supplement provides nutrient substances necessary for human bodies, but becomes a main source of nitrogenous waste and other toxins for uremia patients; the toxin in the body of the uremia patient is removed through dialysis, and simultaneously, the nutritional elements such as protein and the like are lost. In addition, malnutrition is one of the important causative factors of hypertension and anemia.
Second, the survival threat faced by renal dialysis patients varies dynamically with different dialysis sessions. Arrhythmia and sudden death due to hyperkalemia become their major threats in patients with inadequate solute clearance during the early stages of dialysis. With the increased efficiency of dialysis, the major threat is increased by vascular calcification and cardiovascular death risk due to hyperphosphatemia. When using phosphorus-lowering drugs, the major threat is altered to malnutrition due to excessive drop in blood phosphorus levels.
Therefore, it is necessary to perform fine management of dialysis patients, thereby comprehensively improving dialysis complications. Unfortunately, despite the extensive research efforts of researchers in developing products or methods to ameliorate complications in renal dialysis patients, none of the products or methods currently fully address the above-mentioned problems.
The Zhuyonggang and the like are combined with plus-minus eight-ingredient decoction (30 g of medicinal raw astragalus mongholicus, 15g of codonopsis pilosula, 12g of fried bighead atractylodes rhizome, 15g of poria cocos, 9g of angelica sinensis, 15g of prepared rehmannia root, 9g of fried white paeony root, 6g of fructus amomi and 9g of ligusticum wallichii) to treat dialysis patients for six months, so that the malnutrition symptoms of the renal dialysis patients are improved, but the traditional Chinese medicine used in the treatment method is complex in components, the liver and kidney toxicity of the traditional Chinese medicine and the kidney toxicity even aggravate the renal injury of the dialysis patients, and serious gastrointestinal adverse reactions are generated, so that the decoction is not suitable for long-term administration (the Jian and Yongang and the like, plus-minus eight-ingredient decoction' improvement.
Changfeng et al adopt levocarnitine combined with recombinant human erythropoietin and iron agents to treat patients with hemodialysis complications, improve the serological indexes of the patients, but the malnutrition dialysis patients show low response to ESAs, and the administration of ESAs preparations in large dose increases the risk of cardiovascular events of the patients (Changfeng, observation of the effect of levocarnitine combined with recombinant human erythropoietin and iron agents on hemodialysis complications, southern medical research, 1 month in 2018, and 2 nd phase in 27).
CN104082662B discloses a nutrient solution suitable for chronic kidney disease patients requiring dialysis, which comprises 1-2% of maltodextrin, 1-9% of protein, 1-10% of vegetable mixed oil, 0.1-1% of fish oil, 0.1-1% of borage oil, 1-5% of sugar, 1-15% of corn syrup solid, 1-2% of cellulose, 0.1-1% of mineral substances, 0.01-0.1% of emulsifying agent, 0.01-0.05% of L-carnitine and L-taurine, and the balance of water. The nutrient solution is mainly used for the total nutrient supplement of patients and can not meet the clinical requirements of patients needing to supplement special nutrients.
CN105166901A discloses a nutritional composition for dialysis patients, which comprises 270 parts of maltodextrin, 80 parts of chestnut powder, 135 parts of corn syrup, 65 parts of concentrated whey protein, 25 parts of calcium caseinate, 15 parts of sodium caseinate, 27 parts of sunflower seed oil, 15 parts of red beet powder, 5 parts of sucralose and 5 parts of edible spice. The composition is used for improving malnutrition of patients. However, the following disadvantages exist: firstly, the complexity and the production cost of the preparation process are increased by the chestnut powder; secondly, the potassium content of the chestnut powder is more than 4 times higher than that of the apple powder, so that the blood potassium level of a patient with renal dialysis is improved, and complications of high blood potassium can be caused; thirdly, the composition and the proportion of the nutrient components are not in accordance with the requirements of the nephropathy guideline, and the protein energy deficiency, hyperphosphatemia, hyperkalemia, renal hypertension, hypotension after dialysis, anemia and other complications of dialysis patients are difficult to comprehensively improve.
In conclusion, the nutritional protein powder for the renal disease dialysis patient disclosed in the prior art has many defects: (1) the product adopts the soybean protein as the raw material, and lacks the advantages of high purity, reasonable amino acid composition, high absorption, high biological value, high efficiency, high protein efficiency ratio, high utilization rate and the like of the concentrated whey protein; (2) the product contains fructo-oligosaccharide, inulin, chestnut powder and the like, the composition has the protein and energy composition ratio which is difficult to meet the clinical requirements of dialysis patients, and the effect of comprehensively improving the complications of the dialysis patients is poor; (3) the medicine is frequently used, the treatment cost of a patient is improved, the medical insurance burden is increased, the water intake of the patient is large, the kidney burden of a nephropathy patient is increased, and the occurrence risk of serious nephropathy is increased. (4) The existing products or methods for improving the complications of renal dialysis patients mostly improve certain complications of the renal dialysis patients through medicines or nutritional agents, and the curative effect of comprehensively improving the complications of dialysis is very limited.
Therefore, new products for comprehensively improving dialysis complications are urgently needed in clinic, so that the dialysis interval period of a patient is prolonged, the life quality of the patient is improved, the medical expense and expenditure are saved, and the death risk is reduced.
Disclosure of Invention
The invention aims to provide a composition with the effect of preventing and treating complications of dialysis patients, which is characterized by comprising the following components in parts by mass: 5-33 parts of whey protein, 1-20 parts of casein or casein salt, 1-50 parts of maltodextrin, 1-10 parts of corn syrup and 5-75 parts of sunflower seed oil.
In a preferred technical scheme of the invention, the composition comprises the following components in parts by mass: 10-28 parts of whey protein, 2-18 parts of casein or casein salt, 10-40 parts of maltodextrin, 2-8 parts of corn syrup and 10-70 parts of sunflower seed oil.
In a preferred technical scheme of the invention, the composition comprises the following components in parts by mass: 15-23 parts of whey protein, 5-15 parts of casein, 15-35 parts of maltodextrin, 4-6 parts of corn syrup and 31-51 parts of sunflower seed oil.
In a preferred technical scheme of the invention, the composition comprises the following components in parts by mass: 15 parts of whey protein, 15 parts of casein or casein salt, 15 parts of maltodextrin, 4 parts of corn syrup and 51 parts of sunflower seed oil.
In a preferred technical scheme of the invention, the composition comprises the following components in parts by mass: 23 parts of whey protein, 5 parts of casein or casein salt, 35 parts of maltodextrin, 6 parts of corn syrup and 31 parts of sunflower seed oil.
In a preferred technical scheme of the invention, the composition comprises the following components in parts by mass: 23 parts of whey protein, 5 parts of casein or casein salt, 25 parts of maltodextrin, 4 parts of corn syrup and 43 parts of sunflower seed oil.
In the preferred technical scheme of the invention, the composition does not contain saccharide additives and is suitable for being taken by diabetic patients with renal dialysis.
In a preferred embodiment of the present invention, the salt of casein is selected from any one of calcium caseinate, sodium caseinate, potassium caseinate, magnesium caseinate, or a combination thereof.
In the preferred technical scheme of the invention, the salt of the casein is calcium caseinate and sodium caseinate, and the mass ratio of the sodium caseinate to the calcium caseinate is 1 (2-5).
In the preferred technical scheme of the invention, the salt of the casein is calcium caseinate and sodium caseinate, and the mass ratio of the sodium caseinate to the calcium caseinate is 1: 3.5.
In the preferable technical scheme of the invention, the total mass of the composition is 100g, the content of sodium in the composition is less than or equal to 150mg, the content of phosphorus is less than or equal to 105mg, and the content of potassium is less than or equal to 300 mg.
In the preferable technical scheme of the invention, the total mass of the composition is 100g, the content of sodium in the composition is less than or equal to 130mg, the content of phosphorus is less than or equal to 90mg, and the content of potassium is less than or equal to 200 mg.
In the preferable technical scheme of the invention, the total mass of the composition is 100g, and the content of sodium, phosphorus and potassium in the composition is less than or equal to 120mg, 70mg and 80mg respectively.
In a preferred embodiment of the present invention, the composition further comprises a vitamin, preferably the vitamin is selected from vitamin B1Vitamin B2Vitamin B6Vitamin B12Any one or combination of vitamin C, vitamin A, vitamin D, vitamin E, vitamin K, vitamin H, folic acid, pantothenic acid and nicotinic acid.
In a preferred embodiment of the present invention, the composition further comprises trace elements, preferably the trace elements are selected from any one or a combination of zinc, iron, copper and selenium.
The composition of the invention screens and matches whey protein with high biological value protein characteristic. The lactalbumin contains beneficial components such as lactalbumin, beta-lactoglobulin, immunoglobulin, lactoperoxidase, glycomacropeptide and the like, and essential amino acids with complete types and proper proportion, and is easy to digest and absorb by human bodies (the lactalbumin is completely digested and absorbed in vivo for 2-3 hours). The whey protein of the present invention has the following effects: firstly, the composition promotes the synthesis of body protein, corrects the negative nitrogen balance of a patient, improves the nitrogen balance of the body of the patient, increases the lean body mass, and reduces the release of inflammatory factors such as IL-1 alpha, IL-1 beta, IL-10 and the like; secondly, the composition is helpful to reduce and even avoid body damage caused by oxidative stress and inhibit the activity of angiotensin converting enzyme; thirdly, regulating the structure of intestinal flora and enhancing the immunity of the organism; and fourthly, leucine in the whey protein can stimulate the release of insulin, reduce the postprandial blood sugar, obviously improve the protein nutrition condition of a patient and is beneficial to controlling the blood sugar level of the patient.
The composition of the invention is also screened for collocated casein. Casein is a binding protein containing calcium phosphate, is an acid-sensitive slow-release protein (the digestion time in vivo is 5-7 hours), can continuously release nutrient elements, and has the beneficial effects of timely repairing muscle cells, continuously nourishing organisms when a patient sleeps, and the like.
The composition of the invention screens whey protein, casein and the proportion thereof, fully exerts the characteristics of easy digestion of the components in vivo, slow release of protein and the like of the components, continuously provides the required protein energy and nutrition for organisms, is beneficial to correcting the negative nitrogen balance of patients, improves the protein nutrition status of the patients, provides a proper protein energy ratio for the patients, simultaneously stimulates the release of insulin, reduces the postprandial blood sugar, is beneficial to controlling the blood sugar level, and is suitable for dialyzed diabetic patients.
The composition is screened and matched with maltodextrin. The maltodextrin is prepared by taking starch-containing products such as corn, rice and the like as raw materials, performing low-degree controlled hydrolytic conversion by an enzymatic process, purifying and drying. The maltodextrin contains a large amount of polysaccharide, calcium, iron and other trace elements and minerals beneficial to human body, and is used for providing energy for patients, improving the nutrition proportion of the patients and increasing the nutrition value ratio of the patients.
Corn syrup is also screened and matched in the composition. The corn syrup is prepared by hydrolyzing corn starch through various enzymes, the main components of the corn syrup comprise glucose, maltose, oligosaccharide, dextrin and the like, the corn syrup is easy to digest and absorb by human bodies, can quickly supplement energy after being orally taken, can timely correct nutrition deficiency and weak constitution caused by insufficient energy of patients, and has mild and pure taste and low sweetness. But long-term consumption of a large amount of the health-care food can interfere with sugar metabolism, increase the risk of diabetes and increase the metabolic burden of liver and kidney.
The composition is matched with sunflower seed oil in a screening way. The sunflower seed oil contains a large amount of unsaturated fatty acids such as Linoleic Acid (LA) which are necessary for human bodies, can promote the regeneration and growth of cells of the human bodies, protect the health of the skin, reduce the accumulation of cholesterol in blood and effectively reduce the incidence rate of hypertension. The linoleic acid level in blood plasma is increased, the Asymmetric Dimethylarginine (ADMA) level and the interleukin-6 (IL-6) level in the circulation of a patient with hemodialysis can be obviously reduced, and the risk of occurrence of cardiovascular events (CVE) is reduced. The sunflower seed oil contains abundant mineral substances, and is beneficial to supplement trace elements and nutritional ingredients required by patients. The sunflower seed oil also has diuretic effect, and can promote the discharge of phosphorus in blood potassium and blood of patients, and remarkably improve hyperkalemia and hyperphosphatemia of patients. However, the long-term overdose of sunflower seed oil can increase the metabolic burden of liver and kidney.
The composition scientifically screens whey protein, casein, maltodextrin, corn syrup and sunflower seed oil and the proportion thereof, supplements protein energy and required nutrient components in a kidney dialysis patient in time, effectively controls the blood sodium intake, blood potassium intake and blood phosphorus intake of the dialysis patient, avoids complications or adverse reactions caused by excessive intake, and comprehensively improves the complications of hyperphosphatemia, hyperkalemia, hypernatremia, hypertension, anemia and the like of the patient.
The compositions of the present invention may be in various dosage forms well known in the art and may be prepared using formulation techniques conventional in the art. The preparation suitable for the invention is an oral preparation, preferably the oral preparation is selected from any one of granules, powder, tablets, capsules, pills, dripping pills, syrups, mixtures, lotions, effervescent agents, pastes, emulsions, teas, suspensions and liquid preparations (oral liquid), and more preferably any one of powder, suspension, granules, tablets, capsules, effervescent agents and liquid preparations (oral liquid).
In a preferred technical scheme of the invention, a pharmaceutically acceptable carrier is added into the composition, and preferably, the pharmaceutically acceptable carrier is selected from any one or a combination of a filler, a binder, a lubricant, a disintegrating agent, a wetting agent, an emulsifying agent, a preservative, an antioxidant, a stabilizing agent, a flavoring agent or an aromatizing agent.
In a preferred embodiment of the present invention, the filler is selected from any one or a combination of lactose, powdered sugar, dextrin, starch or a derivative thereof, cellulose or a derivative thereof, an inorganic calcium salt, sorbitol, or glycine.
In a preferred embodiment of the present invention, the binder is selected from any one or a combination of syrup, acacia, gelatin, sorbitol, tragacanth, cellulose and its derivatives, starch and its derivatives, and polyvinylpyrrolidone.
In a preferred technical scheme of the invention, the lubricant is selected from any one of or a combination of superfine silica powder, magnesium stearate, talcum powder, aluminum hydroxide, boric acid, hydrogenated vegetable oil and polyethylene glycol.
In a preferred embodiment of the present invention, the disintegrant is selected from any one or a combination of starch or a derivative thereof, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, and microcrystalline cellulose.
In a preferred technical scheme of the invention, the cellulose derivative is selected from any one or combination of microcrystalline cellulose, sodium carboxymethyl cellulose, ethyl cellulose and hydroxypropyl methyl cellulose.
In a preferred technical scheme of the invention, the starch derivative is selected from any one of sodium carboxymethyl starch, sodium starch glycolate, pregelatinized starch, modified starch, hydroxypropyl starch and corn starch or a combination thereof.
In a preferred embodiment of the present invention, the wetting agent is selected from any one of sodium lauryl sulfate, water or alcohol, or a combination thereof.
In a preferred technical scheme of the invention, the emulsifier is selected from any one of polysorbate-80, sorbitan fatty acid, pluronic F-68, lecithin and soybean lecithin or a combination thereof.
In a preferred embodiment of the present invention, the preservative is selected from any one of 0.5% phenol, 0.3% cresol, 0.5% chlorobutanol, or a combination thereof.
In a preferred technical scheme of the invention, the antioxidant is selected from any one of potassium sorbate, sodium sulfite, sodium bisulfite, sodium metabisulfite and dibutylbenzoic acid or a combination thereof.
In a preferred embodiment of the present invention, the stabilizer is selected from any one of glycerol and tween-80 or a combination thereof.
In a preferred technical scheme of the invention, the flavoring agent is any one or combination of glycyrrhizin, maltitol, aspartame, stevioside and acesulfame potassium.
In a preferred technical scheme of the invention, the aromatizer is selected from any one of edible spices and edible essences or the combination thereof.
The invention also aims to provide a method for preparing a composition with the effect of preventing and treating complications of dialysis patients, which is characterized by comprising the following components in parts by mass: 5-33 parts of whey protein, 1-20 parts of casein or casein salt, 1-50 parts of maltodextrin, 1-10 parts of corn syrup and 5-75 parts of sunflower seed oil, and the whey protein, the casein or casein salt, the maltodextrin, the corn syrup and the sunflower seed oil are weighed and uniformly mixed to obtain the feed.
In a preferred technical scheme of the invention, the composition comprises the following components in parts by mass: 10-28 parts of whey protein, 2-18 parts of casein or casein salt, 10-40 parts of maltodextrin, 2-8 parts of corn syrup and 10-70 parts of sunflower seed oil.
In a preferred technical scheme of the invention, the composition comprises the following components in parts by mass: 15-23 parts of whey protein, 5-15 parts of casein, 15-35 parts of maltodextrin, 4-6 parts of corn syrup and 31-51 parts of sunflower seed oil.
In a preferred technical scheme of the invention, the composition comprises the following components in parts by mass: 15 parts of whey protein, 15 parts of casein or casein salt, 15 parts of maltodextrin, 4 parts of corn syrup and 51 parts of sunflower seed oil.
In a preferred technical scheme of the invention, the composition comprises the following components in parts by mass: 23 parts of whey protein, 5 parts of casein or casein salt, 35 parts of maltodextrin, 6 parts of corn syrup and 31 parts of sunflower seed oil.
In a preferred technical scheme of the invention, the composition comprises the following components in parts by mass: 23 parts of whey protein, 5 parts of casein or casein salt, 25 parts of maltodextrin, 4 parts of corn syrup and 43 parts of sunflower seed oil.
In the preferred technical scheme of the invention, the composition does not contain saccharide additives and is suitable for being taken by diabetic patients with renal dialysis.
In a preferred embodiment of the present invention, the salt of casein is selected from any one of calcium caseinate, sodium caseinate, potassium caseinate, magnesium caseinate, or a combination thereof.
In the preferred technical scheme of the invention, the salt of the casein is calcium caseinate and sodium caseinate, and the mass ratio of the sodium caseinate to the calcium caseinate is 1 (2-5).
In the preferred technical scheme of the invention, the salt of the casein is calcium caseinate and sodium caseinate, and the mass ratio of the sodium caseinate to the calcium caseinate is 1: 3.5.
In the preferable technical scheme of the invention, the total mass of the composition is 100g, the content of sodium in the composition is less than or equal to 150mg, the content of phosphorus is less than or equal to 105mg, and the content of potassium is less than or equal to 300 mg.
In the preferable technical scheme of the invention, the total mass of the composition is 100g, the content of sodium in the composition is less than or equal to 130mg, the content of phosphorus is less than or equal to 90mg, and the content of potassium is less than or equal to 200 mg.
In the preferable technical scheme of the invention, the total mass of the composition is 100g, and the content of sodium, phosphorus and potassium in the composition is less than or equal to 120mg, 70mg and 80mg respectively.
In a preferred embodiment of the present invention, the composition further comprises a vitamin, preferably the vitamin is selected from vitamin B1Vitamin B2Vitamin B6Vitamin B12Any one or combination of vitamin C, vitamin A, vitamin D, vitamin E, vitamin K, vitamin H, folic acid, pantothenic acid and nicotinic acid.
In a preferred embodiment of the present invention, the composition further comprises trace elements, preferably the trace elements are selected from any one or a combination of zinc, copper and selenium.
The compositions of the present invention may be in various dosage forms well known in the art and may be prepared using formulation techniques conventional in the art. The preparation suitable for the invention is an oral preparation, preferably the oral preparation is selected from any one of tablets, capsules, granules, pills, powder, pills, syrups, mixtures, lotions, effervescent agents, pastes, emulsions, teas, suspensions and liquid preparations (oral liquid), and more preferably any one of powders, suspensions, granules, tablets, capsules, effervescent agents and liquid preparations (oral liquid).
In a preferred technical scheme of the invention, a pharmaceutically acceptable carrier is added into the composition, and the pharmaceutically acceptable carrier is selected from any one or combination of a filler, a binder, a lubricant, a disintegrating agent, a wetting agent, an emulsifying agent, a disintegrating agent, a preservative, an antioxidant, a stabilizing agent, a flavoring agent or an aromatizing agent.
In a preferred embodiment of the present invention, the filler is selected from any one or a combination of lactose, powdered sugar, dextrin, starch or a derivative thereof, cellulose or a derivative thereof, an inorganic calcium salt, sorbitol, or glycine.
In a preferred embodiment of the present invention, the binder is selected from any one or a combination of syrup, acacia, gelatin, sorbitol, tragacanth, cellulose and its derivatives, starch and its derivatives, and polyvinylpyrrolidone.
In a preferred technical scheme of the invention, the lubricant is selected from any one of or a combination of superfine silica powder, magnesium stearate, talcum powder, aluminum hydroxide, boric acid, hydrogenated vegetable oil and polyethylene glycol.
In a preferred embodiment of the present invention, the disintegrant is selected from any one of starch or its derivatives, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, and microcrystalline cellulose, or a combination thereof, and preferably, the starch derivative is selected from any one of sodium carboxymethyl starch, sodium starch glycolate, pregelatinized starch, modified starch, hydroxypropyl starch, and corn starch, or a combination thereof.
In a preferred embodiment of the present invention, the wetting agent is selected from sodium dodecyl sulfate, water or alcohol; emulsifiers, such as any one of polysorbate-80, sorbitan elaeate, pluronic F-68, lecithin, soy lecithin, or combinations thereof.
In a preferred technical scheme of the invention, the emulsifier is selected from any one of polysorbate-80, sorbitan fatty acid, pluronic F-68, lecithin and soybean lecithin or a combination thereof.
In a preferred embodiment of the present invention, the disintegrant is selected from any one or a combination of starch or a derivative thereof, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, and microcrystalline cellulose.
In a preferred embodiment of the present invention, the preservative is selected from any one of 0.5% phenol, 0.3% cresol, 0.5% chlorobutanol, or a combination thereof.
In a preferred technical scheme of the invention, the antioxidant is selected from any one of potassium sorbate, sodium sulfite, sodium bisulfite, sodium metabisulfite and dibutylbenzoic acid or a combination thereof.
In a preferred embodiment of the present invention, the stabilizer is selected from any one of glycerol and tween-80 or a combination thereof.
In a preferred technical scheme of the invention, the flavoring agent is any one or combination of glycyrrhizin, maltitol, aspartame, stevioside and acesulfame potassium.
In a preferred technical scheme of the invention, the aromatizer is selected from any one of spice, edible spice and flavoring essence or the combination thereof.
Another object of the present invention is to provide the use of the composition of the present invention for the preparation of a preparation for the prevention and treatment of complications in dialysis patients.
In a preferred embodiment of the present invention, the dialysis patient is selected from any one of chronic renal failure dialysis patients, hemodialysis patients, peritoneal dialysis patients, diabetic patients who receive renal dialysis, or a combination thereof.
In a preferred embodiment of the present invention, the complication is any one or a combination of protein energy expenditure, hyperkalemia, hyperphosphatemia, hypernatremia, renal hypertension, hypotension after dialysis, and anemia.
In a preferred embodiment of the present invention, the composition improves the malnutrition of the patient by supplementing the protein energy of the dialysis patient, and provides the protein energy supply ratio of 10 to 20% to the dialysis patient.
In a preferred technical scheme of the invention, the composition promotes phosphorus metabolism in a patient body by adsorbing and dialyzing phosphorus in the patient body, and controls the serum phosphorus level of the patient to be 1.13-1.78 mmol/L.
In a preferable technical scheme of the invention, the composition promotes potassium metabolism in a patient body by adsorbing and dialyzing potassium in the patient body, and controls the serum potassium level of the patient to be less than or equal to 5.0 mol/L.
In a preferable technical scheme of the invention, the composition promotes potassium metabolism in a patient body by adsorbing and dialyzing potassium in the patient body, and controls the serum potassium level of the patient to be less than or equal to 4.0 mol/L.
In a preferred embodiment of the present invention, the composition controls the mean arterial pressure of a patient to 70-105mmHg by improving the weight and nutrition of a dialysis patient.
In a preferred embodiment of the present invention, the composition inhibits protein metabolism in hemodialysis patients, improves malnutrition and anemia symptoms in patients, and helps to reduce the amount of erythropoietin or iron administered to dialysis patients.
In a preferred technical scheme of the invention, the dosage of the composition is 1-2 times per day for adults or 2 times per dialysis day, and the unit dose of the composition taken every time is 23.5 g.
In a preferred embodiment of the invention, the unit dose of the composition of the invention is reconstituted with 60ml of water.
Another object of the present invention is to provide a use of a composition for the preparation of a product for preventing and treating complications in dialysis patients, said composition being used in combination with any one of or a combination of an ameliorating agent for renal anemia, a calcium supplement agent, a phosphorus-reducing agent, a potassium-reducing agent, and an antacid.
In a preferred embodiment of the present invention, the renal anemia-ameliorating agent is selected from any one of iron-supplementing agents and erythropoiesis-stimulating agents (ESAs), or a combination thereof.
In a preferable technical scheme of the invention, the iron supplement agent is any one or a combination of ferrous sulfate, ferrous gluconate, ferrous fumarate, ferrous lactate, ferric chloride, ferric sulfate, ferric pyrophosphate, ferric ammonium citrate, ferric orthophosphate, ferric oxide, ferric hydroxide, starch iron, sucrose iron and heme iron.
In a preferred technical scheme of the invention, the calcium supplement is selected from any one of calcium carbonate, amino acid chelated calcium, calcium citrate, calcium gluconate, calcium acetate and calcium lactate or a combination thereof.
In a preferable technical scheme of the invention, the phosphorus-reducing drug is selected from any one of lanthanum carbonate, calcium acetate and sevelamer or the combination thereof.
In a preferred embodiment of the present invention, the potassium-lowering agent is selected from any one of potassium-lowering resin and diuretic, or a combination thereof.
In a preferable technical scheme of the invention, the diuretic is selected from any one or combination of furosemide, bumetanide, torasemide, hydrochlorothiazide, spironolactone, triamterene and tolvaptan.
In a preferred technical scheme of the invention, the antacid is selected from any one of aluminum hydroxide, sodium bicarbonate, sucralfate, hydrotalcite, omeprazole and bismuth potassium citrate or the combination thereof.
In order to clearly convey the scope of the invention, the invention is defined by the following terms:
1. the "saccharide additive" as used herein refers to monosaccharide, disaccharide and/or polysaccharide, including sucrose, glucose, fructose, lactose, maltose, xylose, sorbose, mannose, etc. The 'sugar additive' is an important nutrient for human body, supplies heat energy to human body and endows the composition with sweet taste. The 'sugar additive' can affect the blood sugar index of human body, and the diabetic should strictly control the daily intake.
2. The trace elements are metal elements which exist in the body in trace amount and are necessary for the normal function of the body.
3. Unless otherwise stated, the protein content in the composition is determined by adopting a Kjeldahl method; determining the fat content of the composition by alkaline hydrolysis; carbohydrate content-fat content-moisture content-ash content-100-protein content; the energy value is calculated by multiplying the content of protein, fat, and carbohydrate per 100g of product by its energy factor 17 (protein), 37 (fat), 17 (carbohydrate). The invention refers to phosphomolybdic acid method to detect the content of phosphorus in blood and refers to ion selective electrode method to detect the content of potassium in blood.
4. Unless otherwise indicated, when the present invention relates to percentages between liquids, said percentages are volume/volume percentages; the invention relates to the percentage between liquid and solid, said percentage being volume/weight percentage; the invention relates to the percentages between solid and liquid, said percentages being weight/volume percentages; the balance being weight/weight percent.
Compared with the prior art, the composition has the following beneficial technical effects:
1. the composition scientifically screens whey protein, casein, sunflower seed oil, maltodextrin and corn syrup and the proportion thereof, fully exerts the effects and the synergistic interaction of various components, and firstly provides sufficient protein energy ratio for dialysis patients, and effectively supplements the protein energy supply ratio to 10-20%; secondly, strictly controlling the contents of sodium, potassium and phosphorus in the composition, meeting the requirements of patients on low sodium, low phosphorus, low potassium and the like, and controlling the blood potassium level of the patients to be less than or equal to 5.0mmol/L and the blood phosphorus level to be less than or equal to 1.78 mmol/L; and thirdly, the complications such as protein malnutrition, hyperphosphatemia, hyperkalemia, hypertension, anemia and the like which are easily caused by a renal dialysis patient are comprehensively improved, the incidence rate of the complications of the dialysis patient is remarkably reduced, the dialysis interval period of the dialysis patient is prolonged, the body damage caused by dialysis is reduced, the living quality of the patient is improved, the death risk is reduced, the medical expense of the patient is saved, and the medical insurance burden is reduced.
2. The recommended administration dose of the composition is 1-2 times per day and 23.5g per time, and the composition is taken with 60mL of water each time, so that the metabolic burden of the kidney is favorably reduced, the risk of hypertension and heart disease caused by excessive liquid intake is reduced, the compliance of a patient is improved, and the patient can reach the liquid intake standard (500mL + urine volume) of a renal dialysis patient recommended by Chinese clinical practice guidelines for nutrition treatment of chronic kidney disease (2018 edition).
3. The composition has no use contraindication, can be used for a long time, can be used together with other medicines, and obviously enlarges the clinical application range.
4. The preparation method of the composition has simple and convenient process, is beneficial to industrial mass production, and has obvious cost benefit.
Detailed Description
The present invention is described below with reference to examples, but the scope of the present invention is not limited to the examples.
Example 1Composition and proportioning research of the composition
The compositions A to R were prepared by weighing the required amounts of the raw materials according to Table 1 and mixing them uniformly by a mixer. The protein and energy contents of the compositions A-R are measured according to the method of the invention, the blood phosphorus content is detected by referring to a phosphomolybdic acid method, and the blood potassium content is detected by referring to an ion selective electrode method, so that 7 groups of compositions A, B, C, D, J, K, M with the protein energy supply ratio of 10-20% are obtained.
140 patients were selected from patients with renal disease who had been hemodialysis three times a week for more than 3 months, and were aged 32-68 years. 140 patients were randomized into 7 groups of 20, each group having no significant difference in age, etiology, course, dialysis regimen, nutritional status, etc. (P > 0.05).
The tested patients take the composition with the protein energy supply ratio of 10-20% every day, and the using amount is as follows: 1 time/day, 23.5 g/time, adding 60ml warm water each time, shaking up, and drinking. After 30 days of administration, the arithmetic mean of the blood potassium and the blood phosphorus of the patients is measured and calculated, and the results are shown in Table 2.
TABLE 1 composition and compounding ratio study
Note: the composition of casein (g) used in table 1 was sodium caseinate: the mass ratio of the calcium caseinate is 1: 3.5.
Table 2 compositions provide protein energizing ratios and their effect on blood phosphorus and potassium values in test patients
As can be seen from Table 2, composition C, D, M provides a protein energy supply ratio of 10-20% and has a serum phosphorus value of less than 1.78mmol/L and a serum potassium value of less than 5.0mmol/L in a patient. The composition of the invention is screened by comprehensively considering the protein energy supply ratio provided by the composition and the blood phosphorus value and the blood potassium value of a patient, and the composition comprises 15-23 parts of whey protein, 5-15 parts of casein, 15-35 parts of maltodextrin, 4-6 parts of corn syrup and 31-51 parts of sunflower seed oil, and comprehensively improves dialysis complications and adverse reactions thereof.
Example 2Preparation of the compositions of the invention
The components and proportions of the compositions 1 to 3 according to the invention are shown in Table 3.
TABLE 3 Components and proportions of compositions 1-3 according to the invention
Numbering | Whey protein (g) | Casein (g) | Maltodextrin (g) | Corn syrup (g) | Sunflower seed oil (g) |
Composition 1 | 15 | 15 | 15 | 4 | 51 |
Composition 2 | 23 | 5 | 35 | 6 | 31 |
Composition 3 | 23 | 5 | 25 | 4 | 43 |
Note: the casein (g) used in table 3 was composed of sodium caseinate: the mass ratio of the calcium caseinate is 1: 3.5.
The preparation method of the compositions 1 to 3 of the invention comprises the following steps: weighing the required amounts of whey protein, sodium caseinate, calcium caseinate, maltodextrin, corn syrup and sunflower seed oil according to table 3, and uniformly mixing by using a mixer to obtain the milk protein powder.
Example 3The composition is used for treating chronic renal failure dialysis patient complication research
1. Subject patient
The patients to be tested are 120 patients with nephropathy which are dialyzed 3 times per week and have hemodialysis time of more than 3 months, the patients to be tested are 32-68 years old, and comprise 52 patients with diabetic nephropathy, 34 patients with primary glomerulonephritis, 23 patients with secondary glomerulonephritis, 5 patients with hypertension benign arteriolar nephrosclerosis, 4 patients with aristolochic acid nephropathy and 2 patients with unknown etiology. Among 120 patients tested, 76% of patients with mild and moderate malnutrition and 24% of patients with severe malnutrition were tested.
2. Experimental methods
Each group of the tested patients receive treatment guidance, and corresponding symptomatic treatment is given according to the specific conditions of the tested patients, wherein the treatment comprises infection resistance, blood sugar control, blood pressure control, anemia correction and the like. The patient is continuously taking the composition of the invention for six months as a treatment course. After the patient takes a course of treatment, the change of the relevant indexes of the tested patient is observed.
The subjects were randomly divided into a blank group (24 cases), a control group (24 cases), an experimental group 1(24 cases), an experimental group 2(24 cases), and an experimental group 3(24 cases). The subjects in each group had no significant differences in sex, age, etiology, course of disease, dialysis regimen, nutritional status, etc. (P > 0.05).
1) Taking normal diet for blank group;
2) the composition and the proportion of the composition taken by the control group are as follows: 270 parts of maltodextrin, 80 parts of chestnut powder, 135 parts of corn syrup, 65 parts of concentrated whey protein, 25 parts of calcium caseinate, 15 parts of sodium caseinate, 27 parts of sunflower seed oil, 15 parts of red beet powder, 5 parts of sucralose and 5 parts of edible spice. The control subjects were administered the control composition in the following amounts: 1 time/day, 135 g/time, and is taken with 360mL of boiled water each time;
3) experimental groups 1-3 were administered compositions 1-3 of the present invention, respectively. The dosage of the composition 1-3 of the invention taken by the tested patient is as follows: the medicine is taken after being mixed with 60ml of warm water for 1 time per day and 23.5g per time.
3. Observation index
The weight gain during dialysis, albumin and prealbumin, blood phosphorus level, blood potassium level and the incidence rate and the satisfaction degree of patients of complications (such as abnormal blood pressure, abdominal pain, arrhythmia, hyperkalemia, heart failure and the like) during dialysis before and after the intervention of the tested patients are detected.
The test result is subjected to data processing by SPSS 16.0 statistical software, the mean value plus or minus standard deviation is adopted for representation, t test is adopted, X2 test is adopted for counting data, and the difference with P less than 0.05 has statistical significance. See tables 4-5.
TABLE 4 Albumin, Pre-Albumin, body weight, serum phosphorus, serum Potassium values before and after intervention
Note:acomparing the prognosis of each group with the pre-intervention self P is less than 0.05;bcomparing P to be less than 0.05 after the intervention of the experimental group and the blank group;ccomparing P to be less than 0.05 after intervention of the control group and the blank group;dthe P of the experimental group is less than 0.05 after the intervention of the control group.
TABLE 5 incidence of complications during dialysis and patient satisfaction
Note:acomparing the P of the experimental group and the blank group during the dialysis period to be less than 0.05;bcomparing the control group with the blank group, wherein P is less than 0.05;cthe P of the experimental group is less than 0.05 after the intervention of the control group.
As can be seen from Table 4, the test patients and the control patients had elevated albumin, prealbumin levels, and body weight, and decreased serum potassium and serum phosphorus values after receiving the dry prognosis. Compared with a control group, the improvement level of the composition 1-3 is more remarkable, wherein the blood potassium content of the tested patient of the composition 1-3 is reduced to below 4.0mmol/L from more than 5.0mmol/L before intervention, and the blood phosphorus content is reduced to below 1.78mmol/L from a high blood potassium value of 2.2mmol/L before intervention.
As can be seen from Table 5, after the subjects had received the dry prognosis, the incidence of complications of blood pressure abnormality, abdominal pain, arrhythmia, hyperkalemia, and heart failure was reduced in the subjects of the experimental group and the control group. Compared with a control group, the compositions 1 to 3 have more obvious control effect on abdominal pain, arrhythmia, hyperkalemia, heart failure complication or adverse reaction of patients, and the composition 1 to 3 needs less water for infusing, thus being beneficial to reducing the metabolic burden of the kidney of the patients.
The results show that the composition is suitable for comprehensively improving complications and adverse reactions of renal dialysis patients.
The above description of the specific embodiments of the present invention is not intended to limit the present invention, and those skilled in the art may make various changes and modifications according to the present invention without departing from the spirit of the present invention, which is defined in the appended claims.
Claims (10)
1. The composition for treating complications of dialysis patients is characterized by comprising the following components in parts by mass: the composition comprises the following components, 5-33 parts of whey protein, 1-20 parts of casein or casein salt, 1-50 parts of maltodextrin, 1-10 parts of corn syrup and 5-75 parts of sunflower seed oil.
2. The composition according to claim 1, which comprises the following components in parts by mass: 10-28 parts of whey protein, 2-18 parts of casein or casein salt, 10-40 parts of maltodextrin, 2-8 parts of corn syrup and 10-70 parts of sunflower seed oil.
3. The composition according to any one of claims 1-2, which is free of carbohydrate additives and suitable for administration to diabetic patients under renal dialysis.
4. Composition according to any one of claims 1 to 3, wherein the salt of casein is selected from any one of calcium caseinate, sodium caseinate, potassium caseinate, magnesium caseinate or a combination thereof.
5. The composition according to any one of claims 1 to 4, wherein the composition has a sodium content of 150mg or less, a phosphorus content of 105mg or less, and a potassium content of 300mg or less, based on 100g of the total mass; preferably, the total mass of the composition is 100g, and the content of sodium in the composition is less than or equal to 130mg, the content of phosphorus in the composition is less than or equal to 90mg, and the content of potassium in the composition is less than or equal to 200 mg; most preferably, the total mass of the composition is 100g, and the content of sodium in the composition is less than or equal to 120mg, the content of phosphorus in the composition is less than or equal to 70mg, and the content of potassium in the composition is less than or equal to 80 mg.
6. The composition according to any one of claims 1 to 5, which contains a vitamin selected from any one of vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin A, vitamin D, vitamin E, vitamin K, vitamin H, folic acid, pantothenic acid and nicotinic acid, or a combination thereof; preferably, the composition further comprises trace elements, preferably trace elements selected from any one or combination of zinc, copper and selenium.
7. The preparation method of the composition for treating the complications of dialysis patients is characterized in that the composition comprises the following components in parts by mass: 5-33 parts of whey protein, 1-20 parts of casein or casein salt, 1-50 parts of maltodextrin, 1-10 parts of corn syrup and 5-75 parts of sunflower seed oil, and the whey protein, the casein or casein salt, the maltodextrin, the corn syrup and the sunflower seed oil are weighed and uniformly mixed to obtain the feed.
8. Use of the composition according to any one of claims 1 to 6 or the composition prepared by the preparation method according to claim 7 for preparing a preparation for preventing and treating complications of dialysis patients.
9. The use according to claim 8, wherein the dialysis patient is selected from any one of chronic renal failure dialysis patients, hemodialysis patients, peritoneal dialysis patients, diabetic patients receiving renal dialysis, or a combination thereof.
10. The use according to any one of claims 8 to 9, wherein the complications of dialysis patients are selected from any one of protein energy expenditure, hyperkalemia, hyperphosphatemia, hypernatremia, renal hypertension, hypotension after dialysis, anemia, or a combination thereof; preferably, the composition provides a protein supply ratio of 10-20% to a dialysis subject, and/or controls the subject's serum phosphorus level to 1.13-1.78mmol/L, and/or controls the subject's serum potassium level to less than or equal to 5.0mol/L, and/or controls the subject's mean arterial pressure to 70-105 mmHg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010902260.3A CN112535729B (en) | 2019-09-20 | 2019-09-20 | Composition with effect of preventing and treating complications of dialysis patients, and preparation method and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910890455.8A CN110538315B (en) | 2019-09-20 | 2019-09-20 | Composition with effect of preventing and treating complications of dialysis patients and preparation method and application thereof |
CN202010902260.3A CN112535729B (en) | 2019-09-20 | 2019-09-20 | Composition with effect of preventing and treating complications of dialysis patients, and preparation method and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910890455.8A Division CN110538315B (en) | 2019-09-20 | 2019-09-20 | Composition with effect of preventing and treating complications of dialysis patients and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112535729A true CN112535729A (en) | 2021-03-23 |
CN112535729B CN112535729B (en) | 2024-06-14 |
Family
ID=68714104
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010902260.3A Active CN112535729B (en) | 2019-09-20 | 2019-09-20 | Composition with effect of preventing and treating complications of dialysis patients, and preparation method and application thereof |
CN201910890455.8A Active CN110538315B (en) | 2019-09-20 | 2019-09-20 | Composition with effect of preventing and treating complications of dialysis patients and preparation method and application thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910890455.8A Active CN110538315B (en) | 2019-09-20 | 2019-09-20 | Composition with effect of preventing and treating complications of dialysis patients and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN112535729B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116270975A (en) * | 2023-04-10 | 2023-06-23 | 江西健乐医疗科技有限公司 | Composition for preventing and treating complications of kidney disease dialysis patients, preparation method and application thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111671080A (en) * | 2020-05-14 | 2020-09-18 | 安盛(深圳)医药科技有限公司 | Composition for enhancing immunity, low-phosphorus whey protein powder and preparation method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008156868A2 (en) * | 2007-06-20 | 2008-12-24 | Baum Seth J | Compositions and methods of treating chronic kidney disease |
CN105166901A (en) * | 2015-09-17 | 2015-12-23 | 广州市红十字会医院 | Nutrient composition for hemodialysis patient |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030031757A1 (en) * | 2001-08-03 | 2003-02-13 | Kraft Food Holdings, Inc. | Stable and bioavailable iron fortified beverages |
CN109805377A (en) * | 2019-02-28 | 2019-05-28 | 黑龙江阳光工业大麻研究院 | A kind of hypoglycemic special medicine purposes formula food and preparation method thereof |
-
2019
- 2019-09-20 CN CN202010902260.3A patent/CN112535729B/en active Active
- 2019-09-20 CN CN201910890455.8A patent/CN110538315B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008156868A2 (en) * | 2007-06-20 | 2008-12-24 | Baum Seth J | Compositions and methods of treating chronic kidney disease |
CN105166901A (en) * | 2015-09-17 | 2015-12-23 | 广州市红十字会医院 | Nutrient composition for hemodialysis patient |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116270975A (en) * | 2023-04-10 | 2023-06-23 | 江西健乐医疗科技有限公司 | Composition for preventing and treating complications of kidney disease dialysis patients, preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN110538315B (en) | 2020-09-18 |
CN110538315A (en) | 2019-12-06 |
CN112535729B (en) | 2024-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109452521B (en) | Auxiliary uric acid peptide reducing solid beverage, preparation method and application | |
RU2356247C2 (en) | Combinations and compositions containing fatty acids and amino acids, their application for prevention and delay of progressing or treatment of diabetes and diabetes associated diseases and conditions, method of weight reduction in mammal, kit | |
US8703209B2 (en) | Composition and method for modulating hydrogen ion physiology | |
CN101496580B (en) | Special diet and foodstuffs formula containing small peptide for diabetic | |
US20090142410A1 (en) | Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise | |
US10485836B2 (en) | Anti-fatigue composition used for increasing endurance performance, and use of the same | |
EP2011500B1 (en) | Fat accumulation inhibitor for the treatment of metabolic syndrome | |
CN101022821A (en) | Use of aspartate for regulating glucose levels in blood | |
CN102935231A (en) | Treatments using citrulline | |
US8703719B1 (en) | Method and composition for improved muscle performance | |
WO2000045651A1 (en) | Oral arginine and insulin secretion | |
ZA200600818B (en) | Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus | |
CN110538315B (en) | Composition with effect of preventing and treating complications of dialysis patients and preparation method and application thereof | |
WO2014071176A1 (en) | Nutritional supplements including meal replacements and related methods | |
CN112189711A (en) | Milk powder for assisting in reducing hypertension, hyperglycemia and hyperlipidemia of middle-aged and old people | |
CN108606269B (en) | Sports nutritional supplement and preparation method thereof | |
CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
KR20070095338A (en) | Hepatic function remedial agent | |
CN105581331B (en) | Calcium supplement nutritional composition | |
CN105166901A (en) | Nutrient composition for hemodialysis patient | |
CN112715961A (en) | Food composition for promoting muscle growth of elderly diabetic patients | |
JPWO2018179441A1 (en) | Prevention or improvement of insulin resistance | |
CN115702654A (en) | Middle-aged and old-aged modified goat milk powder assisting in reducing blood sugar and preparation method thereof | |
RU2400251C1 (en) | Method of treating chronic kidney disease in predialytic and dialytic periods and medication for its realisation | |
JP2001048794A (en) | Health food and medicinal composition which contain mixture of powder originated from leaf of mulberry and powder originated from oyster and is used for treating niddm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |